Item Type | Name |
Academic Article
|
Comprehensive genomic characterization of squamous cell lung cancers.
|
Academic Article
|
miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1.
|
Concept
|
Carcinoma, Non-Small-Cell Lung
|
Concept
|
Lung Neoplasms
|
Concept
|
Carcinoma, Lewis Lung
|
Concept
|
Lung Diseases, Interstitial
|
Concept
|
Small Cell Lung Carcinoma
|
Concept
|
Lung
|
Academic Article
|
Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy.
|
Academic Article
|
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.
|
Academic Article
|
Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
|
Academic Article
|
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
|
Academic Article
|
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
|
Academic Article
|
Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells.
|
Academic Article
|
Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
|
Academic Article
|
Mesothelioma and small cell lung cancer.
|
Academic Article
|
Targeted therapies for lung cancer: clinical experience and novel agents.
|
Academic Article
|
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
|
Academic Article
|
Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells.
|
Academic Article
|
The BATTLE trial: personalizing therapy for lung cancer.
|
Academic Article
|
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
|
Academic Article
|
Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.
|
Academic Article
|
Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.
|
Academic Article
|
An integrin ?3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.
|
Academic Article
|
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
|
Academic Article
|
Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer.
|
Academic Article
|
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
|
Academic Article
|
The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies.
|
Academic Article
|
Lung cancer.
|
Academic Article
|
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
|
Academic Article
|
Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer.
|
Academic Article
|
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
|
Academic Article
|
Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.
|
Academic Article
|
Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence.
|
Academic Article
|
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.
|
Academic Article
|
Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer.
|
Academic Article
|
Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients.
|
Academic Article
|
Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters.
|
Academic Article
|
The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.
|
Academic Article
|
Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis.
|
Academic Article
|
C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression.
|
Academic Article
|
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
|
Academic Article
|
Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
|
Academic Article
|
Comprehensive molecular profiling of lung adenocarcinoma.
|
Academic Article
|
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.
|
Academic Article
|
Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.
|
Academic Article
|
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.
|
Academic Article
|
ZD6474--clinical experience to date.
|
Academic Article
|
The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors.
|
Academic Article
|
Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
|
Academic Article
|
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
|
Academic Article
|
Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer.
|
Academic Article
|
Angiogenesis inhibitors for lung cancer: clinical developments and future directions.
|
Academic Article
|
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.
|
Academic Article
|
Second-line treatment of advanced non-small cell lung cancer.
|
Academic Article
|
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
|
Academic Article
|
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
|
Academic Article
|
HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice.
|
Academic Article
|
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
|
Academic Article
|
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.
|
Academic Article
|
Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
|
Academic Article
|
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.
|
Academic Article
|
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
|
Academic Article
|
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
|
Academic Article
|
Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy.
|
Academic Article
|
Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer.
|
Academic Article
|
Farnesyl transferase inhibitors for patients with lung cancer.
|
Academic Article
|
Emerging antiangiogenic agents in lung cancer.
|
Academic Article
|
Mouse models of lung cancer.
|
Academic Article
|
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
|
Academic Article
|
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
|
Academic Article
|
Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy.
|
Academic Article
|
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
|
Academic Article
|
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
|
Academic Article
|
KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling.
|
Academic Article
|
Her2-targeted therapies in non-small cell lung cancer.
|
Academic Article
|
Vascular endothelial growth factor accelerates compensatory lung growth after unilateral pneumonectomy.
|
Academic Article
|
Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus.
|
Academic Article
|
Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536.
|
Academic Article
|
Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer.
|
Academic Article
|
Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.
|
Academic Article
|
VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy.
|
Academic Article
|
A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer.
|
Academic Article
|
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.
|
Academic Article
|
Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.
|
Academic Article
|
Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.
|
Academic Article
|
An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2.
|
Academic Article
|
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
|
Academic Article
|
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
|
Academic Article
|
Predictive biomarkers in precision medicine and drug development against lung cancer.
|
Academic Article
|
Can the Lung Cancer Pie Be Divided into Angiogenic Slices?
|
Academic Article
|
SABR vs surgery for NSCLC in the media.
|
Academic Article
|
In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation.
|
Academic Article
|
TGF?1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy.
|
Academic Article
|
Epithelial-mesenchymal transition predicts polo-like kinase 1 inhibitor-mediated apoptosis in non-small cell lung cancer
|
Academic Article
|
Focal adhesion kinase regulates the DNA damage response and its inhibition radiosensitizes mutant KRAS lung cancer
|
Academic Article
|
Activation of the PI3K/mTOR pathway following PARP inhibition in small cell lung cancer
|
Academic Article
|
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities
|
Academic Article
|
Predictive biomarkers in precision medicine and drug development against lung cancer
|
Academic Article
|
Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma
|
Academic Article
|
Image analysis-based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non-small cell lung carcinoma patients
|
Academic Article
|
Genomic heterogeneity of multiple synchronous lung cancer
|
Academic Article
|
In vivo delivery of miR-34a sensitizes lung tumors to radiation through RAD51 regulation
|
Academic Article
|
Small-cell lung cancer
|
Academic Article
|
An integrated molecular analysis of lung adenocarcinomas identifies potential therapeutic targets among TTF1-negative tumors, including DNA Repair Proteins and Nrf2
|
Academic Article
|
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations
|
Academic Article
|
Small cell lung cancer
|
Academic Article
|
HIF2α cooperates with RAS to promote lung tumorigenesis in mice (Journal of Clinical Investigation (2009) 119, (2160-2170) doi
|
Academic Article
|
Different dietary patterns and reduction of lung cancer risk
|
Academic Article
|
TGFβ1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy
|
Academic Article
|
STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment
|
Academic Article
|
Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition
|
Academic Article
|
Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells
|
Academic Article
|
Bevacizumab beyond disease progression for advanced non-small cell lung cancer
|
Academic Article
|
Can the lung cancer pie be divided into angiogenic slices?
|
Academic Article
|
Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma
|
Academic Article
|
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy
|
Academic Article
|
Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition
|
Academic Article
|
Stage I lung cancer-to operate or to radiate? That is the question
|
Academic Article
|
Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.
|
Academic Article
|
Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing.
|
Academic Article
|
RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer.
|
Academic Article
|
Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer.
|
Academic Article
|
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.
|
Academic Article
|
Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations.
|
Academic Article
|
Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma.
|
Academic Article
|
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
|
Academic Article
|
Bevacizumab beyond disease progression for advanced non-small cell lung cancer: Does persistence have its rewards?
|
Academic Article
|
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?
|
Academic Article
|
Prognostic Factors as a Function of Disease-free Interval After Definitive (Chemo)radiation for Non-Small Cell Lung Cancer Using Conditional Survival Analysis.
|
Academic Article
|
Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
|
Academic Article
|
Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells.
|
Academic Article
|
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.
|
Academic Article
|
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
|
Academic Article
|
Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.
|
Academic Article
|
Different dietary patterns and reduction of lung cancer risk: A large case-control study in the U.S.
|
Academic Article
|
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
|
Academic Article
|
Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.
|
Academic Article
|
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.
|
Academic Article
|
Axl Receptor Axis: A New Therapeutic Target in Lung?Cancer.
|
Academic Article
|
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
|
Academic Article
|
Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients.
|
Academic Article
|
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
|
Academic Article
|
Stage I lung cancer-to operate or to radiate? that is the question.
|
Academic Article
|
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.
|
Academic Article
|
Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapy.
|
Academic Article
|
Genomic heterogeneity of multiple synchronous lung cancer.
|
Academic Article
|
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
|
Academic Article
|
Consolidative local therapy in oligometastatic patients - Authors' reply.
|
Academic Article
|
Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.
|
Academic Article
|
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
|
Academic Article
|
The Influence of Body Mass Index on Overall Survival?Following Surgical Resection of Non-Small Cell Lung Cancer.
|
Academic Article
|
DNA methylation intratumor heterogeneity in localized lung adenocarcinomas.
|
Academic Article
|
Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.
|
Academic Article
|
CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.
|
Academic Article
|
Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.
|
Academic Article
|
Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.
|
Academic Article
|
Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer.
|
Academic Article
|
Long-Term Outcomes of Salvage Stereotactic Ablative?Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
|
Academic Article
|
7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
|
Academic Article
|
Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer.
|
Academic Article
|
MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk.
|
Academic Article
|
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
|
Academic Article
|
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.
|
Academic Article
|
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ?-blockers.
|
Academic Article
|
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer.
|
Academic Article
|
Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
|
Academic Article
|
Quantitative Proteomic Analysis of Optimal Cutting Temperature (OCT) Embedded Core-Needle Biopsy of Lung Cancer.
|
Academic Article
|
Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies.
|
Academic Article
|
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
|
Academic Article
|
Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma.
|
Academic Article
|
Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models.
|
Academic Article
|
eIF2?, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer.
|
Academic Article
|
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
|
Academic Article
|
Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors.
|
Academic Article
|
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
|
Academic Article
|
Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
|
Academic Article
|
Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.
|
Academic Article
|
Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer.
|
Academic Article
|
Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer.
|
Academic Article
|
Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer.
|
Academic Article
|
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
|
Academic Article
|
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.
|
Academic Article
|
Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer.
|
Academic Article
|
Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.
|
Academic Article
|
Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer.
|
Academic Article
|
De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer.
|
Academic Article
|
Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers.
|
Academic Article
|
Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).
|
Academic Article
|
Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis.
|
Academic Article
|
Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.
|
Academic Article
|
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
|
Academic Article
|
Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.
|
Academic Article
|
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.
|
Academic Article
|
Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer.
|
Academic Article
|
Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.
|
Academic Article
|
Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer.
|
Academic Article
|
Author Correction: Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer.
|
Academic Article
|
LCE: an open web portal to explore gene expression and clinical associations in lung cancer.
|
Academic Article
|
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
|
Academic Article
|
PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
|
Academic Article
|
Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease.
|
Academic Article
|
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.
|
Academic Article
|
Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer.
|
Academic Article
|
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
|
Academic Article
|
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma.
|
Academic Article
|
Author Correction: CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.
|
Academic Article
|
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.
|
Academic Article
|
Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
|
Academic Article
|
Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer.
|
Academic Article
|
Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.
|
Academic Article
|
Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma.
|
Academic Article
|
Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice.
|
Academic Article
|
Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
|
Academic Article
|
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Na?ve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
|
Academic Article
|
Co-occurring genomic alterations in?non-small-cell lung cancer biology and therapy.
|
Academic Article
|
Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141].
|
Academic Article
|
Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer.
|
Academic Article
|
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC.
|
Academic Article
|
Correction: LCE: an open web portal to explore gene expression and clinical associations in lung cancer.
|
Academic Article
|
Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer.
|
Academic Article
|
Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells.
|
Academic Article
|
Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer.
|
Academic Article
|
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses.
|
Academic Article
|
The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
|
Academic Article
|
Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial.
|
Academic Article
|
Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation.
|
Academic Article
|
?-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers.
|
Academic Article
|
Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation.
|
Academic Article
|
High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.
|
Academic Article
|
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy.
|
Academic Article
|
Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.
|
Academic Article
|
Metabolic Responses to Metformin in Inoperable Early-stage Non-Small Cell Lung Cancer Treated With Stereotactic Radiotherapy: Results of a Randomized Phase II Clinical Trial.
|
Academic Article
|
Comprehensive T cell repertoire characterization of non-small cell lung cancer.
|
Academic Article
|
Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy.
|
Academic Article
|
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
|
Academic Article
|
A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer.
|
Academic Article
|
Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.
|
Academic Article
|
Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report.
|
Academic Article
|
18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer.
|
Academic Article
|
Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort.
|
Academic Article
|
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.
|
Academic Article
|
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
|
Academic Article
|
An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis.
|
Academic Article
|
What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer.
|
Academic Article
|
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.
|
Academic Article
|
Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.
|
Academic Article
|
Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively.
|
Academic Article
|
Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers.
|
Academic Article
|
Outcomes to first-line pembrolizumab in patients with PD-L1-high (=50%) non-small cell lung cancer and a poor performance status.
|
Academic Article
|
Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma.
|
Academic Article
|
Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab.
|
Academic Article
|
Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy.
|
Academic Article
|
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components.
|
Academic Article
|
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC.
|
Academic Article
|
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer.
|
Academic Article
|
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial.
|
Academic Article
|
Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC.
|
Academic Article
|
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.
|
Academic Article
|
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
|
Academic Article
|
AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors.
|
Academic Article
|
Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC.
|
Academic Article
|
Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.
|
Academic Article
|
Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity.
|
Academic Article
|
STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition.
|
Academic Article
|
Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC.
|
Academic Article
|
Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.
|
Academic Article
|
New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung Cancer.
|
Academic Article
|
KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations.
|
Academic Article
|
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma.
|
Academic Article
|
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
|
Academic Article
|
Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas.
|
Academic Article
|
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer.
|
Academic Article
|
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
|
Academic Article
|
Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment.
|
Academic Article
|
Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer.
|
Academic Article
|
Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma.
|
Academic Article
|
Global analysis of shared T?cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery.
|
Academic Article
|
Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients.
|
Academic Article
|
Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
|
Academic Article
|
Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.
|
Academic Article
|
Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing.
|
Academic Article
|
Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features.
|
Academic Article
|
Author Correction: Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma.
|
Academic Article
|
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer.
|
Academic Article
|
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial.
|
Academic Article
|
Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology.
|
Academic Article
|
Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC.
|
Academic Article
|
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
|
Academic Article
|
Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling.
|
Academic Article
|
ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC.
|
Academic Article
|
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer.
|
Academic Article
|
Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.
|
Academic Article
|
Structure-based classification predicts drug response in EGFR-mutant NSCLC.
|
Academic Article
|
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.
|
Academic Article
|
Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.
|
Academic Article
|
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer.
|
Academic Article
|
Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado.
|
Academic Article
|
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
|
Academic Article
|
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab?+?Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial.
|
Academic Article
|
Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations.
|
Academic Article
|
Outcomes of Critically Ill Lung Cancer Patients Initiating Targeted Therapy or Immunotherapy in the Intensive Care Unit: A Single-Center Report.
|
Academic Article
|
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
|
Academic Article
|
Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer.
|
Academic Article
|
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung?cancer.
|
Academic Article
|
Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.
|
Academic Article
|
The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics.
|
Academic Article
|
Hitting the Right Spot: Advances in the Treatment of NSCLC With Uncommon EGFR Mutations.
|
Academic Article
|
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping.
|
Academic Article
|
In Response.
|
Academic Article
|
Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer.
|
Academic Article
|
Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection.
|
Academic Article
|
Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes.
|
Academic Article
|
Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer.
|
Academic Article
|
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer.
|
Academic Article
|
Germline and Somatic Smoothened Mutations in Non-Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib.
|
Academic Article
|
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.
|
Academic Article
|
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
|
Academic Article
|
Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer.
|
Academic Article
|
Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.
|
Academic Article
|
Targeting IL-1? as an immunopreventive and therapeutic modality for K-ras-mutant lung cancer.
|
Academic Article
|
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T?cells.
|
Academic Article
|
Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-Small Cell Lung Cancer with EGFR Mutations (NORTHSTAR).
|
Academic Article
|
Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma.
|
Academic Article
|
Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab.
|
Academic Article
|
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
|
Academic Article
|
Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer.
|
Academic Article
|
Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma.
|
Academic Article
|
Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment.
|
Academic Article
|
Antibody-drug conjugates in lung cancer: dawn of a new era?
|
Academic Article
|
High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.
|
Academic Article
|
Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set.
|
Academic Article
|
Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
|
Academic Article
|
A STING operation to expose KRAS and STK11 co-mutated lung cancers.
|
Academic Article
|
A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations.
|
Academic Article
|
Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial.
|
Academic Article
|
IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC.
|
Academic Article
|
Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival.
|
Academic Article
|
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer.
|
Academic Article
|
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.
|
Academic Article
|
Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of?Recurrence in Stage I Non-Small Cell Lung Cancer.
|
Academic Article
|
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
|
Academic Article
|
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).
|
Academic Article
|
Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives.
|
Academic Article
|
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
|
Academic Article
|
Glucocorticoid mediated inhibition of LKB1 mutant non-small cell lung cancers.
|
Academic Article
|
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
|
Academic Article
|
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience.
|
Academic Article
|
Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer.
|
Academic Article
|
Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.
|
Academic Article
|
Clinical outcomes of immunotherapy continued beyond radiographic disease progression in older adult patients with advanced non-small cell lung cancer.
|
Academic Article
|
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study.
|
Academic Article
|
MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.
|
Academic Article
|
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial.
|
Academic Article
|
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
|
Academic Article
|
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.
|
Academic Article
|
Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer.
|
Academic Article
|
Unfolding the secrets of small cell lung cancer progression: Novel approaches and insights through rapid autopsies.
|
Academic Article
|
Perioperative and oncologic outcomes of pulmonary resection for synchronous oligometastatic non-small cell lung cancer: Evidence for surgery in advanced disease.
|
Academic Article
|
International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
|
Academic Article
|
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
|
Academic Article
|
Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer.
|
Academic Article
|
ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.
|
Academic Article
|
Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma.
|
Academic Article
|
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.
|
Academic Article
|
Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer.
|
Academic Article
|
Automated Cellular-Level Dual Global Fusion of Whole-Slide Imaging for Lung Adenocarcinoma Prognosis.
|
Academic Article
|
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
|
Academic Article
|
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.
|
Academic Article
|
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
|
Academic Article
|
Effects of KRAS Genetic Interactions on Outcomes in Cancers of the Lung, Pancreas, and Colorectum.
|
Academic Article
|
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC.
|
Academic Article
|
Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer.
|
Academic Article
|
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.
|
Academic Article
|
Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events.
|
Academic Article
|
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. Reply.
|
Academic Article
|
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes.
|
Academic Article
|
Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma.
|
Academic Article
|
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.
|
Academic Article
|
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
|
Academic Article
|
An atlas of epithelial cell states and plasticity in lung adenocarcinoma.
|
Academic Article
|
Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy.
|
Academic Article
|
Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept.
|
Academic Article
|
Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screening.
|
Academic Article
|
Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer.
|
Academic Article
|
Author Correction: An atlas of epithelial cell states and plasticity in lung adenocarcinoma.
|
Academic Article
|
Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights.
|
Academic Article
|
Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features.
|